Posts
Media
Videos
Starter Packs
btnin24.bsky.social
@btnin24.bsky.social
· Apr 24
Cost analysis of the TB-PRACTECAL clinical trial on novel tuberculosis treatment regimens
Clinical trials are considered to be the largest contributor to pharmaceutical development costs. However, public disclosure of the costs of individual clinical trials is rare. Médecins Sans Frontiè...
journals.plos.org
Reposted
Reposted
btnin24.bsky.social
@btnin24.bsky.social
· Feb 18
The Effectiveness and Safety of Bedaquiline, Pretomanid, and Linezolid (BPaL)–Based Regimens for Rifampicin-Resistant Tuberculosis in Non-Trial Settings—A Prospective Cohort Study in Belarus and Uzbek...
Treatment for multidrug-resistant/rifampicin-resistant tuberculosis (TB) and pre–extensively drug-resistant TB using 24-week all-oral bedaquiline, pretoman
academic.oup.com
Reposted
btnin24.bsky.social
@btnin24.bsky.social
· Jan 31
24-week, all-oral regimens for pulmonary rifampicin-resistant tuberculosis in TB-PRACTECAL trial sites: an economic evaluation
This trial-based evidence adds to consistent indications from modelling studies that
BPaL-based regimens are cost-saving for both the patient and health system. Urgent
implementation of BPaL-based reg...
www.thelancet.com
Reposted
Reposted
Reposted